

Amin Foroughi Nezhad<sup>1</sup>

<sup>1</sup>Corresponding Author: Faculty of Basic Sciences, Department of Biological Science,  
Semnan University

August 16, 2022

# Glioblastoma and the presence of extra - chromosomal DNA: a novel perspective at the genesis of cancerous tumors

Amin Foroughi Nezhad\*

\* Corresponding Author: Faculty of Basic Sciences, Department of Biological Science, Semnan University, Semnan, Iran; Email: [aminforoughy.77@gmail.com](mailto:aminforoughy.77@gmail.com)

**Abstract:** One of the greatest common main cancerous tumor of the brain in adults is glioblastoma, which is fatal without treatment. For individuals diagnosed having glioblastoma, typical gold level treatment consists of surgical removal of the tumor supported by radiation treatment plus concurrent chemotherapy drugs. Despite this, overall, prognostic level is still dismal; approximately 12- to 15-month life expectancy is typical. Cell signaling, angiogenesis, Gene mutation have all been highlighted as promising areas to explore in the lookout for potential treatments, thanks to years of study. The pathophysiology of glioblastoma is now much more complicated due to new discoveries of extrachromosomal DNA (ecDNA). Numerous oncogenes found within those ecDNAs, which seem to be important driving therapeutic resistance, faster tumor progression and intra-tumoral heterogeneity, are also found in cancer cells nucleus, where their genome size is noticeably larger. Existing knowledge regarding therapy significance, tumor growth and ecDNA synthesis in glioblastoma will indeed be reviewed in this article.

**Keywords:** Extracellular vesicles, Therapy resistance, Diagnosis, Oncogene amplification, EcDNA, Glioblastoma

---

## 1. Introduction

One of the most deadly cancerous tumors of the Central Nervous System is glioblastoma. Due to its elevated levels of heterogeneity in the both conditions of inter- and intra-tumor, the malignancies are resistant to treatment. Glioblastoma is characterized by its genomic diversity, as well as with the existence of stem cells of tumor-initiation. ecDNA has emerged as a key factor in the development as well as heterogeneity of glioblastoma. Findings from neuroblastoma karyotyping research and pediatric brain cancer cells have long shown the presence of tiny ecDNA segments [1,2]. Neither the functionality nor the synthesis of such ecDNA were understood at the stage of their identification. Through the use of bioinformatics methods and modern biology, we have identified a number of oncogenes that are widely transcribed within cancer cells' ecDNA. The double-minute chromosomes, also termed as ecDNAs, are structures that have self-replication in various dimensions that may be generally divided between microDNAs of size less than 1 Kb and huge circulate DNA of size more than 100 Kb to 5 Mb [3,4]. The majority of them are produced throughout the repair of DNA, recombination and replication, when the DNA undergoes an annealing and re-circularization mechanism. The entire genes and regulating portions of ecDNAs can be seen under a microscope [5]. The involvement of this ecDNA in tumorigenesis and its

development is crucial. The ecDNAs biosynthesis and oncogenesis, their distribution and potential connection to extracellular vesicles, as well as the utilization of ecDNAs in the management and treatment of glioblastoma, will all be covered in this study.

## **2. EcDNA implementation for the intended applications of Diagnosis and Treatment**

In some kind of a process known as liquid biopsy, circulation of nucleic acids are indeed being researched as less infiltrative indicators for the prediction and identification of many cancers [6]. According to a latest investigations, the amount of cancer growth and the development of neoplasia are correlated with variations in the amounts of circulated nucleotides. Since this is the case, researchers are dedicated to creating cutting-edge methods of using circulated nucleic acids in cancer diagnosis and prediction. Nevertheless, owing to the existence of endonuclease in blood, cell free circulation of nucleic acids have a relatively limited half-life (15 minute to couple of hours), as well as being rapidly removed from the circulation via kidney and liver [7]. Instead, ecDNA and other circular DNA seems to be more stable and anticipated to persist for considerably longer compared to the linear DNA following discharge from cells to the circulation because it is incapable of being digested by exonucleases [8]. Data suggests the ecDNA is present in the human blood, implying that cell-free ecDNAs might be used as possible markers for prompt identification and prognosis [9]. Cyclic DNAs provide a unique challenge for liquid biopsy since they are said to be released to the blood stream from normal and malignant tissues. Kumar et al found, though, that tumor-derived ecDNA is much larger in size than normal tissue. ecDNA [10]. Researchers additionally noted that a reduction in the circulating ecDNA length following surgery could suggest a successful result, and a future increase in length could signify a relapse of the cancer. Moreover, Kumar et al. recognized over 18,000 larger ecDNAs and smaller microDNAs in glioma cell cultures through the utilizing of an assay for transposase-accessible chromatin using sequencing (ATAC-seq) [11]. Numerous of the larger ecDNAs carried established cancer genetic markers, such as EGFR, which have been further affirmed via metaphase FISH and inverse PCR [11]. Treatment sensitivity In addition, researchers stated that ATAC-seq might be utilized to anticipate treatment sensitivity and identify ecDNA in a malignancy prior to amplification [11]. Life expectancy for individuals whose tumors were carried with ecDNA were found to be considerably lower than those of individuals whose tumors were not caused via ecDNA, according to a latest research [12]. If ecDNA are to be used as prognosis factors in the long term, their potential must first be uncovered via extensive research. Promising therapies for stopping cancer's spread and increasing patients' lives could be discovered by learning further about ecDNA's function in amplifying oncogene in tumor development [4]. Novel drugs aimed against ecDNA in different tumors are being developed by modern investigations [13]. Thus, drugs that can specifically target ecDNA could provide a unique therapeutic window for glioblastoma.

## **3. Glioblastoma and ecDNA's potential to promote tumor progression**

Using sequence readings that join amplified DNA fragments, researchers may now find ecDNAs through employing recently developed Amplicon Architect method [4]. Glioblastoma ecDNA factors are found to incorporate oncogenes such as Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2), Mouse double minute 2 homolog (MDM2), cyclin-dependent kinase (CDK4/6), Mesenchymal to epithelial transition (MET), Platelet derived growth factor receptor alpha (PDGFRA), Epidermal growth factor receptor (EGFR) and Myelocytomatosis

(MYC)[24,14–18]. Additional confirmation of the existence of such oncogenes was provided through metaphase neurosphere of glioblastoma, patient-derived xenograft (PDX) model and fluorescent in-situ hybridization (FISH) method using a probe which is specific to the oncogene in tumor [24,14,15]. Glioblastoma also has a much increased replica frequency of ecDNA, indicating an abundance of oncogenes. The architectural enhancer in ecDNA has been shown to affect carcinogenic transcriptional control, as described by Morton et al. As a further piece of evidence, researchers hypothesized that regional enhancer factors are virtually invariably present in ecDNA sequences alongside oncogenes [19]. This discovery clarified the increased transcription of oncogenes linked to ecDNA. Research demonstrates that secondary somatic mutations, such as deletions, insertions and point mutations, may arise in ecDNAs, even further indicating that the course of glioblastoma is continually altering in initial malignancies, after therapy, and even following recurrence [24,18]. Finally, throughout the development of glioma, genomic heterogeneity may rapidly grow without modifications to chromosome due to the unequal ecDNA distribution in daughter cells [24]. Another possible factor in the establishment of heterogeneity and the progression of tumors in glioblastoma is amplifying oncogenes on ecDNA. Increased expression of extrachromosomal oncogenes may help tumors thrive in the dynamic environments that promote their sensitivity to treatment, hostility, longevity and growth [4, 18]. In order to facilitate tumor invasion and progression, the local microenvironment could be orchestrated by the transmission of ecDNA that is oncogenic through use of EVs to surrounding cells.

#### **4. ecDNA transit, distribution and synthesis**

The synthesis of ecDNA stays unclear, particularly on a biochemical level. Disagreement amongst scientists has arisen due to a dearth of supporting data regarding the emergence of ecDNA. Inhibiting current replicating, for instance, has been shown to raise ecDNA rates in the past [20]. Instead, contradictory evidence suggests that ecDNAs may arise without Replicating of DNA. The Origin- Dependent Inverted-Repeat Amplification (ODIRA) concept was developed to explain replicating instability, which is thought to be among the processes of ecDNA synthesis [21, 22]. According to the ODIRA concept, a replicating mistake might happen at already present reversed, interrupted and short repetitive segments [21, 22]. Through displacing freshly produced DNA Template, the nearby forks of replicating cause the formation of single-stranded DNA containing circular loops as a consequence of replicating stoppage. Additionally, the ssDNA serves as a template to produce ecDNA with a complementary dsDNA backbone. The synthesis of ecDNA is also thought to be heavily influenced by mechanisms of DNA repairing, according to the results that have been by far the most frequently recognized [23]. It is believed that the mechanisms of DNA repair, including homologous recombination (HR) and nonhomologous end joining (NHEJ), regulate the circulating pathways involved in ecDNA synthesis. Latest research showed that the synthesis of ecDNA in glioblastoma is significantly influenced by the NHEJ DNA repair mechanism utilizing ligase IV, unlike the HR process, which is crucial for encapsulating DNA double-strand fractures [3, 24, 25]. Furthermore, chromothripsis, that breaks the chromosome into many pieces that may be rearranged inside the chromosome, or the releasing of DNA segments, which may be circulated to produce ecDNA, are disastrous occurrences [5]. After the initial formation of ecDNAs, further ecDNA clones are made by the ecDNAs themselves throughout the cell cycle in S stage [24]. Because ecDNAs do not have centromeres, they are distributed unequally among daughter cells during cell

division. In certain tumors, such as glioblastoma multiforme (GBM), ecDNAs split mostly to the cytoplasmic space [24, 26]. Evidence suggests that ecDNAs migrate from the exterior of nucleus to the nuclear core in G1, where they are amplified at the beginning of S stage of the cell cycle [24]. Due to their absence of centromeres, it could be fascinating to learn how ecDNAs are transported return towards the nucleus just at the ending of cell division. Does anybody know whether the ecDNAs have nuclear localization signals (NLSs)? There could be biomolecules called "nuclear importers" that help get them to the nucleoplasm. This leaves important concerns unanswered, since there are still significant voids in our knowledge of ecDNA localisation. In glioblastoma cells, some massive extracellular vesicles of have been demonstrated to possess ecDNAs containing the c-MYC and EGFR genes, which is an important discovery [27]. Therefore, it is probable that cytoplasmic ecDNAs being transmitted toward other nearby cells through extracellular vesicles or expelled during necrosis. These ecDNA-carrying vesicles also could infiltrate blood vessels through the use of a mechanism termed transcytosis mechanism. Glioblastoma pathophysiology therefore relies heavily on ecDNAs being transported in extracellular vesicles.

## **5. Conclusion**

There has been a great deal of progress in our understanding of ecDNA linked to the tumor as well as its involvement in neoplasia after its detection. But, the research into the molecular basis of ecDNA production is lacking. As an added complication, it is unknown where the ecDNAs seen in the blood of normal people come from. In order to determine the ecDNA source in the long term, it will be necessary to analyze the ecDNA's post-biosynthesis alternation. Research on the transmission of ecDNA through extracellular vesicles are also critical for comprehending the glioblastoma pathogenesis. Numerous intriguing occurrences related to ecDNA-regulated pathogenicity have been noted in latest research. Decarvalho et al. revealed, for example, that amplifications of carcinogenic ecDNA were greatly reduced in neurosphere cells but occurred frequently following cerebral installation [24]. Due to this feature, ecDNA may undergo biosynthesis and subsequent re-unification from the chromosome as required foundation or in response to a certain microenvironment. Nevertheless, it remains to be determined what biochemical circuit controls the ecDNA presence and removal in gliomas in response to their environment. Both oncogenes and non-coding areas were discovered by scanning ecDNA components produced from neuroblastoma cells as part of whole-genome sequencing (WGS) data [16]. Scacheri team's [19] discovery that enhancer elements may be found in ecDNA is compatible with our results. Non-coding ecDNA segments have been hypothesized to be transcribed into RNA molecules with important regulatory functions for both chromosomal and ecDNA genes. In addition, ecDNA attracts a lot of interest from scientists all around the globe, and more research is needed to figure out the biomolecular aspects of ecDNA-regulated pathogenesis in glioblastoma cancerous tumors.

**Funding:** N/A

## References

- [1] COX D, YUNCKEN C, SPRIGGS AI. MINUTE CHROMATIN BODIES IN MALIGNANT TUMOURS OF CHILDHOOD. *Lancet*. 1965 Jul 10;1(7402):55-8. doi: 10.1016/s0140-6736(65)90131-5. PMID: 14304929.
- [2] LUBS HA Jr, SALMON JH. THE CHROMOSOMAL COMPLEMENT OF HUMAN SOLID TUMORS. II. KARYOTYPES OF GLIAL TUMORS. *J Neurosurg*. 1965 Feb;22:160-8. doi: 10.3171/jns.1965.22.2.0160. PMID: 14291674.
- [3] Vogt N, Lefèvre SH, Apiou F, Dutrillaux AM, Cör A, Leuraud P, Poupon MF, Dutrillaux B, Debatisse M, Malfoy B. Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. *Proc Natl Acad Sci U S A*. 2004 Aug 3;101(31):11368-73. doi: 10.1073/pnas.0402979101. Epub 2004 Jul 21. PMID: 15269346; PMCID: PMC509208.
- [4] Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, Kornblum HI, Taylor MD, Kaushal S, Cavenee WK, Wechsler-Reya R, Furnari FB, Vandenberg SR, Rao PN, Wahl GM, Bafna V, Mischel PS. Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. *Nature*. 2017 Mar 2;543(7643):122-125. doi: 10.1038/nature21356. Epub 2017 Feb 8. PMID: 28178237; PMCID: PMC5334176.
- [5] Verhaak RGW, Bafna V, Mischel PS. Extrachromosomal oncogene amplification in tumour pathogenesis and evolution. *Nat Rev Cancer*. 2019 May;19(5):283-288. doi: 10.1038/s41568-019-0128-6. PMID: 30872802; PMCID: PMC7168519.
- [6] Aghamir SMK, Heshmat R, Ebrahimi M, Khatami F. Liquid Biopsy: The Unique Test for Chasing the Genetics of Solid Tumors. *Epigenet Insights*. 2020 Feb 28;13:2516865720904052. doi: 10.1177/2516865720904052. PMID: 32166219; PMCID: PMC7050026.
- [7] Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer--a survey. *Biochim Biophys Acta*. 2007 Jan;1775(1):181-232. doi: 10.1016/j.bbcan.2006.10.001. Epub 2006 Oct 7. PMID: 17137717.
- [8] BENDICH A, WILCZOK T, BORENFREUND E. CIRCULATING DNA AS A POSSIBLE FACTOR IN ONCOGENESIS. *Science*. 1965 Apr 16;148(3668):374-6. doi: 10.1126/science.148.3668.374. PMID: 14261529.
- [9] Zhu J, Zhang F, Du M, Zhang P, Fu S, Wang L. Molecular characterization of cell-free eccDNAs in human plasma. *Sci Rep*. 2017 Sep 8;7(1):10968. doi: 10.1038/s41598-017-11368-w. PMID: 28887493; PMCID: PMC5591271.
- [10] Kumar P, Dillon LW, Shibata Y, Jazaeri AA, Jones DR, Dutta A. Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation. *Mol Cancer Res*. 2017 Sep;15(9):1197-1205. doi: 10.1158/1541-7786.MCR-17-0095. Epub 2017 May 26. PMID: 28550083; PMCID: PMC5581709.
- [11] Kumar P, Kiran S, Saha S, Su Z, Paulsen T, Chatrath A, Shibata Y, Shibata E, Dutta A. ATAC-seq identifies thousands of extrachromosomal circular DNA in cancer and cell lines. *Sci Adv*. 2020 May 15;6(20):eaba2489. doi: 10.1126/sciadv.aba2489. PMID: 32440553; PMCID: PMC7228742.
- [12] Kim H, Nguyen NP, Turner K, Wu S, Gujar AD, Luebeck J, Liu J, Deshpande V, Rajkumar U, Namburi S, Amin SB, Yi E, Menghi F, Schulte JH, Henssen AG, Chang HY, Beck CR, Mischel PS, Bafna V, Verhaak RGW. Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. *Nat Genet*. 2020 Sep;52(9):891-897. doi: 10.1038/s41588-020-0678-2. Epub 2020 Aug 17. PMID: 32807987; PMCID: PMC7484012.

- [13] Circular DNA Throws Gene Regulation for a Loop. *Cancer Discov.* 2020 Feb;10(2):170. doi: 10.1158/2159-8290.CD-ND2019-016. Epub 2020 Jan 6. PMID: 31907167.
- [14] Xu K, Ding L, Chang TC, Shao Y, Chiang J, Mulder H, Wang S, Shaw TI, Wen J, Hover L, McLeod C, Wang YD, Easton J, Rusch M, Dalton J, Downing JR, Ellison DW, Zhang J, Baker SJ, Wu G. Structure and evolution of double minutes in diagnosis and relapse brain tumors. *Acta Neuropathol.* 2019 Jan;137(1):123-137. doi: 10.1007/s00401-018-1912-1. Epub 2018 Sep 28. PMID: 30267146; PMCID: PMC6338707.
- [15] Sanborn JZ, Salama SR, Grifford M, Brennan CW, Mikkelsen T, Jhanwar S, Katzman S, Chin L, Haussler D. Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. *Cancer Res.* 2013 Oct 1;73(19):6036-45. doi: 10.1158/0008-5472.CAN-13-0186. Epub 2013 Aug 12. PMID: 23940299; PMCID: PMC3800429.
- [16] Koche RP, Rodriguez-Fos E, Helmsauer K, Burkert M, MacArthur IC, Maag J, Chamorro R, Munoz-Perez N, Puiggròs M, Dorado Garcia H, Bei Y, Röefzaad C, Bardinnet V, Szymansky A, Winkler A, Thole T, Timme N, Kasack K, Fuchs S, Klironomos F, Thiessen N, Blanc E, Schmelz K, Künkele A, Hundsdörfer P, Rosswog C, Theissen J, Beule D, Deubzer H, Sauer S, Toedling J, Fischer M, Hertwig F, Schwarz RF, Eggert A, Torrents D, Schulte JH, Henssen AG. Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. *Nat Genet.* 2020 Jan;52(1):29-34. doi: 10.1038/s41588-019-0547-z. Epub 2019 Dec 16. Erratum in: *Nat Genet.* 2020 Feb 27;: PMID: 31844324; PMCID: PMC7008131.
- [17] Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel PS. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. *Science.* 2014 Jan 3;343(6166):72-6. doi: 10.1126/science.1241328. Epub 2013 Dec 5. PMID: 24310612; PMCID: PMC4049335.
- [18] Nikolaev S, Santoni F, Garieri M, Makrythanasis P, Falconnet E, Guipponi M, Vannier A, Radovanovic I, Bena F, Forestier F, Schaller K, Dutoit V, Clement-Schatlo V, Dietrich PY, Antonarakis SE. Extrachromosomal driver mutations in glioblastoma and low-grade glioma. *Nat Commun.* 2014 Dec 4;5:5690. doi: 10.1038/ncomms6690. PMID: 25471132; PMCID: PMC4338529.
- [19] Morton AR, Dogan-Artun N, Faber ZJ, MacLeod G, Bartels CF, Piazza MS, Allan KC, Mack SC, Wang X, Gimple RC, Wu Q, Rubin BP, Shetty S, Angers S, Dirks PB, Sallari RC, Lupien M, Rich JN, Scacheri PC. Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. *Cell.* 2019 Nov 27;179(6):1330-1341.e13. doi: 10.1016/j.cell.2019.10.039. Epub 2019 Nov 21. PMID: 31761532; PMCID: PMC7241652.
- [20] Sunnerhagen P, Sjöberg RM, Karlsson AL, Lundh L, Bjursell G. Molecular cloning and characterization of small polydisperse circular DNA from mouse 3T6 cells. *Nucleic Acids Res.* 1986 Oct 24;14(20):7823-38. doi: 10.1093/nar/14.20.7823. PMID: 3774548; PMCID: PMC311817.
- [21] Brewer BJ, Payen C, Di Rienzi SC, Higgins MM, Ong G, Dunham MJ, Raghuraman MK. Origin-Dependent Inverted-Repeat Amplification: Tests of a Model for Inverted DNA Amplification. *PLoS Genet.* 2015 Dec 23;11(12):e1005699. doi: 10.1371/journal.pgen.1005699. PMID: 26700858; PMCID: PMC4689423.
- [22] Paulsen T, Kumar P, Koseoglu MM, Dutta A. Discoveries of Extrachromosomal Circles of DNA in Normal and Tumor Cells. *Trends Genet.* 2018 Apr;34(4):270-278. doi: 10.1016/j.tig.2017.12.010. Epub 2018 Jan 9. PMID: 29329720; PMCID: PMC5881399.
- [23] Tanaka H, Watanabe T. Mechanisms Underlying Recurrent Genomic Amplification in Human Cancers. *Trends Cancer.* 2020 Jun;6(6):462-477. doi: 10.1016/j.trecan.2020.02.019. Epub 2020 Mar 24. PMID: 32383436; PMCID: PMC7285850.

[24] deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Multani A, Jiang Y, Zhang J, Nam DH, Petricoin EF, Chin L, Mikkelsen T, Verhaak RGW. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. *Nat Genet.* 2018 May;50(5):708-717. doi: 10.1038/s41588-018-0105-0. Epub 2018 Apr 23. PMID: 29686388; PMCID: PMC5934307.

[25] Cohen Z, Bacharach E, Lavi S. Mouse major satellite DNA is prone to eccDNA formation via DNA Ligase IV-dependent pathway. *Oncogene.* 2006 Aug 3;25(33):4515-24. doi: 10.1038/sj.onc.1209485. Epub 2006 Mar 20. PMID: 16547499.

[26] Koga T, Li B, Figueroa JM, Ren B, Chen CC, Carter BS, Furnari FB. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development. *Neuro Oncol.* 2018 Sep 3;20(10):1310-1320. doi: 10.1093/neuonc/noy058. PMID: 29660021; PMCID: PMC6120357.

[27] Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, Skog J. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. *Nat Commun.* 2011 Feb 1;2:180. doi: 10.1038/ncomms1180. PMID: 21285958; PMCID: PMC3040683.